Overview

Peripheral Stem Cell Transplant in Treating Patients With Multiple Myeloma

Status:
Completed
Trial end date:
2010-02-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Peripheral blood stem cell transplant using stem cells from the patient or a donor may be able to replace immune cells that were destroyed by chemotherapy used to kill tumor cells. The donated stem cells may also help destroy any remaining cancer cells (graft-versus-tumor effect). PURPOSE: This phase II trial is studying how well autologous peripheral stem cell transplant followed by donor peripheral stem cell transplant works in treating patients with multiple myeloma.
Phase:
Phase 2
Details
Lead Sponsor:
Alliance for Clinical Trials in Oncology
Collaborator:
National Cancer Institute (NCI)
Treatments:
Cyclophosphamide
Fludarabine
Fludarabine phosphate
Melphalan
Methotrexate
Tacrolimus